^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HER-2 negative + AR positive + ER positive

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; ESR1, Era, ESR, NR3A1, ER, ER beta; AR, AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1, Androgen receptor
    Entrez ID:
    2064; 2099; 367
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Associations

    News

    Trials
    3d
    A Case of Tubular Carcinoma of the Breast (PubMed, Gan To Kagaku Ryoho)
    Tubular carcinoma is pathologically characterized by a high amount of fibrous stroma surrounding the lumen, and ultrasound findings often show a hypoechoic mass with unclear boundaries and attenuation of posterior echoes. In this case, ultrasound examination was also useful in estimating the histological type.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    7d
    Temporal Trends in Clinicopathological Features and Outcomes of De Novo Metastatic Luminal A Breast Cancer: A Retrospective Multicenter Analysis (2017-2025). (PubMed, Cancer Invest)
    These findings suggest a temporal shift toward a more aggressive biological phenotype, underscoring the clinical relevance of monitoring proliferation indices even within the Luminal A subtype. While causality cannot be inferred, identification of a clinically actionable Ki-67 threshold may aid risk stratification and supports future research integrating molecular profiling to clarify mechanisms underlying temporal biological change.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 negative + AR positive + ER positive
    15d
    CLINICAL RELEVANCE OF HORMONAL RECEPTOR EXPRESSION IN BREAST CANCER: AN IMMUNOHISTOCHEMICAL STUDY FROM TRIPOLI, LIBYA. (PubMed, Exp Oncol)
    The findings highlight the predominance of hormone receptor-positive and HER2-negative tumors in this Libyan cohort.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 expression • HR positive + HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    20d
    AutoEpiCollect 2.0: A Web-Based Machine Learning Tool for Personalized Peptide Cancer Vaccine Design. (PubMed, Molecules)
    Furthermore, by applying RNAseq in a standardized workflow, the approach enables both patient-specific and population-level vaccine design, based on statistically frequent gene variants observed across tumor datasets. AutoEpiCollect 2.0 is freely available as a website based tool for user to design vaccine.
    Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA2 (Breast cancer 2, early onset) • AHNAK2 (AHNAK Nucleoprotein 2) • MUC5AC (Mucin 5AC)
    |
    ER positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    21d
    LaPemERLA: Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole (clinicaltrials.gov)
    P2, N=40, Recruiting, National Cancer Centre, Singapore | Trial completion date: Sep 2027 --> Dec 2027 | Trial primary completion date: Sep 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • letrozole
    22d
    Assessing barriers to genomic testing in breast cancer among diverse patients: a qualitative community-engaged research study. (PubMed, Breast Cancer Res Treat)
    Equitable delivery of genomic testing in breast cancer requires multilevel interventions targeting structural barriers, administrative complexity, and culturally tailored education. Addressing these barriers is likely to reduce disparities and further improve health equity in cancer care.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    1m
    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis (clinicaltrials.gov)
    P2, N=16, Recruiting, Wake Forest University Health Sciences | Trial primary completion date: Dec 2025 --> May 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • ER negative • HER-2 negative + AR positive + ER positive
    |
    methotrexate IV
    1m
    Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer (clinicaltrials.gov)
    P4, N=75, Recruiting, Hebei Medical University Fourth Hospital | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Oct 2024 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Avastin (bevacizumab)
    1m
    Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • fulvestrant
    2ms
    PANSY: Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer (clinicaltrials.gov)
    P3, N=1560, Active, not recruiting, Fudan University | Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Jul 2027 | Trial primary completion date: Jul 2021 --> Jul 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • cyclophosphamide • epirubicin
    2ms
    Encapsulated papillary carcinoma with invasion in the breast: A case report with imaging findings. (PubMed, Radiol Case Rep)
    Postoperative recovery was uneventful, and she remained recurrence-free on tamoxifen therapy for 2 years. This case highlights key imaging features suggestive of invasion in EPC, which may facilitate preoperative assessment and management.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    tamoxifen
    3ms
    Utility of Quantitative Parameters From Triple-Phase Contrast Enhanced Dual-Energy CT for Predicting Immunohistochemical Biomarkers in Invasive Breast Cancer. (PubMed, J Med Imaging Radiat Oncol)
    Triple-phase DECT-derived parameter AEF was identified as a useful negativity predictor for ER and PR levels, while ERVE was demonstrated as a positivity predictor of HER2 status in invasive breast cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive